Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms, reported its financial results for Q2 2023.

The company's CEO, Iris Bincovich, expressed excitement about the positive trajectory and strategic focus on integrating cannabinoids with established drugs.

"We are thrilled with the significant growth we achieved in the second quarter," Bincovich stated. "Our strategic focus is on integrating cannabinoids with existing proven drugs alongside the robust sales from our subsidiary, …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.